Fatma Dedeoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatma Dedeoglu has a total of 460 co-authors. Here are the top co-authors by number of shared publications:
- Lauren A. Henderson
Boston Children's Hospital Harvard Medical School Boston Massachusetts
10 shared publications - Mindy S. Lo
Boston Children's Hospital Boston Massachusetts
10 shared publications - Peter A. Nigrovic
Division of Immunology, Boston Children’s Hospital, Boston, MA
9 shared publications - Pui Y. Lee
Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
8 shared publications - Holly Wobma
Boston Children's Hospital Harvard Medical School Boston Massachusetts
7 shared publications - Margaret H. Chang
Boston Children's Hospital Boston Massachusetts
6 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by Wiley in Arthritis Care & Research
Validation of Patient‐Reported Outcomes Measurement Information System ( PROMIS ) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis
Objective: To assess the validity of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Pediatric measures in patients with chronic nonbacterial osteomyelitis (CNO). Methods: Within the longitudinal patient registry of CNO, English‐speaking patients aged 8 years and older self‐reported PROMIS Pediatric measures of fatigue, pain interference (PI), pain behavior (PB), mobility, upper extremity (UE), physical activity (PA), and strength impact (SI), and external validation measures. Log‐transformed linear mixed‐effects models with random patient intercepts were used to assess PROMIS T‐score changes. Wilcoxon signed‐rank test was performed to determine the PROMIS T‐score changes among the improved, worsened, and unchanged groups. Spearman rank correlation test determined the relationship of PROMIS T‐scores with disease status reported by patients/families. Results: More than 1,000 clinical visits from 184 patients included PROMIS Pediatric measures entries. All PROMIS T‐scores correlated significantly ( P < 0.01) with patient‐reported variables and physician global assessment (PHGA). The correlation between function and mobility, PB, and PI was good (r = 0.4–0.6). The correlation of patient‐reported disease status was strong with PHGA (r = 0.75); moderate with mobility, PB, and PI; and weak with fatigue, SI, UE, and PA. The changes of PROMIS T‐scores over time for mobility, PB, PA, and PI compared with the self‐reported status change were significant ( P < 0.05). After effective treatment, when clinical disease activity score improved by at least three points (n = 18), the change of PROMIS T‐scores for mobility, PB, PI, and UE were significant ( P < 0.05). Conclusion: This study provided evidence supporting the use of PROMIS Pediatric mobility, PB, and PI measures for CNO clinical disease monitoring.
- 6 September 2026
- Published by Wiley in Arthritis Care & Research
Open AccessValidation of Patient‐Reported Outcomes Measurement Information System ( PROMIS ) Pediatric Measures for Children With Chronic Nonbacterial Osteomyelitis
Objective: To assess the validity of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Pediatric measures in patients with chronic nonbacterial osteomyelitis (CNO). Methods: Within the longitudinal patient registry of CNO, English‐speaking patients aged 8 years and older self‐reported PROMIS Pediatric measures of fatigue, pain interference (PI), pain behavior (PB), mobility, upper extremity (UE), physical activity (PA), and strength impact (SI), and external validation measures. Log‐transformed linear mixed‐effects models with random patient intercepts were used to assess PROMIS T‐score changes. Wilcoxon signed‐rank test was performed to determine the PROMIS T‐score changes among the improved, worsened, and unchanged groups. Spearman rank correlation test determined the relationship of PROMIS T‐scores with disease status reported by patients/families. Results: More than 1,000 clinical visits from 184 patients included PROMIS Pediatric measures entries. All PROMIS T‐scores correlated significantly ( P < 0.01) with patient‐reported variables and physician global assessment (PHGA). The correlation between function and mobility, PB, and PI was good (r = 0.4–0.6). The correlation of patient‐reported disease status was strong with PHGA (r = 0.75); moderate with mobility, PB, and PI; and weak with fatigue, SI, UE, and PA. The changes of PROMIS T‐scores over time for mobility, PB, PA, and PI compared with the self‐reported status change were significant ( P < 0.05). After effective treatment, when clinical disease activity score improved by at least three points (n = 18), the change of PROMIS T‐scores for mobility, PB, PI, and UE were significant ( P < 0.05). Conclusion: This study provided evidence supporting the use of PROMIS Pediatric mobility, PB, and PI measures for CNO clinical disease monitoring.
- Open Access
- 29 August 2026
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1)
Neurological manifestations and vasculopathy in PLCG2–associated antibody deficiency and immune dysregulation (APLAID): a case series
Autosomal dominant pathogenic variants in PLCG2 are associated with autoinflammation and PLCG2–associated antibody deficiency and immune dysregulatio
- 29 August 2026
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1)
Open AccessNeurological manifestations and vasculopathy in PLCG2–associated antibody deficiency and immune dysregulation (APLAID): a case series
Autosomal dominant pathogenic variants in PLCG2 are associated with autoinflammation and PLCG2–associated antibody deficiency and immune dysregulatio
- Open Access
- 25 December 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 734-742
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Objective: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity. Methods: Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting. Results: We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant‐negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408). Conclusion: We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.
- 25 December 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 734-742
Open AccessDiagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Objective: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity. Methods: Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting. Results: We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant‐negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408). Conclusion: We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.
- 1 November 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Congruence Between Child Self-Reported and Caregiver-Proxy–Reported Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Objective: To explore congruence between child self-reported and caregiver-proxy–reported health-related quality of life (HRQOL) over time in juvenile idiopathic arthritis (JIA) and childhood-onset systemic lupus erythematosus (cSLE), and to identify factors associated with the level of congruence. Methods: Data were from an observational, longitudinal cohort study conducted to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) measures. HRQOL was assessed at baseline, 6, and 12 months. Four hundred fifty-one children (8-17 years) diagnosed with JIA or cSLE and their caregivers completed the PROMIS Pediatric and Parent Proxy measures, respectively. A 1-way random-effects model was used to estimate the intraclass correlation coefficient (ICC) for congruence between child and caregiver reports, and multivariable mixed-effect models were used to identify associated demographic and clinical factors. Results: The study cohort (87.1% JIA) had a mean age of 13.8 years and were 71.4% female. Across all HRQOL domains, child self-reported and caregiver-proxy–reported mobility, physical activity, fatigue, pain interference, depressive symptoms, and psychological stress had moderate associations (ICC 0.50-0.68), whereas child self-reported and caregiver-proxy–reported family relationships and anxiety were weakly associated (ICC 0.34-0.42). Older children had higher congruence with their caregivers on symptom domains (0.25 to 0.75 points) than younger children; female children had higher congruence with their caregivers on psychological symptoms (−2.20 to −1.98 points) than male children. Conclusion: Caregivers provide complementary information on the physical aspects of HRQOL, with a tendency to estimate worse symptoms and decreased functioning. Child self-report remains the gold standard for understanding HRQOL in pediatric populations with rheumatic diseases.
- 1 November 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
Congruence Between Child Self-Reported and Caregiver-Proxy–Reported Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Objective: To explore congruence between child self-reported and caregiver-proxy–reported health-related quality of life (HRQOL) over time in juvenile idiopathic arthritis (JIA) and childhood-onset systemic lupus erythematosus (cSLE), and to identify factors associated with the level of congruence. Methods: Data were from an observational, longitudinal cohort study conducted to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) measures. HRQOL was assessed at baseline, 6, and 12 months. Four hundred fifty-one children (8-17 years) diagnosed with JIA or cSLE and their caregivers completed the PROMIS Pediatric and Parent Proxy measures, respectively. A 1-way random-effects model was used to estimate the intraclass correlation coefficient (ICC) for congruence between child and caregiver reports, and multivariable mixed-effect models were used to identify associated demographic and clinical factors. Results: The study cohort (87.1% JIA) had a mean age of 13.8 years and were 71.4% female. Across all HRQOL domains, child self-reported and caregiver-proxy–reported mobility, physical activity, fatigue, pain interference, depressive symptoms, and psychological stress had moderate associations (ICC 0.50-0.68), whereas child self-reported and caregiver-proxy–reported family relationships and anxiety were weakly associated (ICC 0.34-0.42). Older children had higher congruence with their caregivers on symptom domains (0.25 to 0.75 points) than younger children; female children had higher congruence with their caregivers on psychological symptoms (−2.20 to −1.98 points) than male children. Conclusion: Caregivers provide complementary information on the physical aspects of HRQOL, with a tendency to estimate worse symptoms and decreased functioning. Child self-report remains the gold standard for understanding HRQOL in pediatric populations with rheumatic diseases.
- Open Access
- 6 June 2025
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 23 (1) , 1-7
Juvenile localized scleroderma: a large retrospective cohort study from a tertiary care center
Juvenile localized scleroderma is a rare pediatric inflammatory disease that primarily affects the skin and subcutaneous tissue but also has the potential to impact deeper tissues and can be associated with extracutaneous manifestations, leading to substantial impairment and disability. Management approaches vary, but in recent years, expert groups have attempted to streamline the approach to care with consensus treatment plans. This retrospective cohort study included pediatric juvenile localized scleroderma patients with ≥ 3 years of follow-up identified within a 21-year period (1999–2020) at a single tertiary care pediatric hospital in the USA. Data on demographics, disease characteristics, and treatment trends were analyzed, with a focus on systemic versus topical therapy and treatment trends before and after the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012. A total of 101 juvenile localized scleroderma patients fulfilled our inclusion criteria. Sixty-three patients were treated with systemic therapy, and 38 were treated with topical therapy. Patients on systemic therapy were more commonly treated in a combined rheumatology-dermatology program (67%) or rheumatology clinic (30%), whereas those on topical therapy were primarily treated in a dermatology clinic (71%). Starting in 2013, a significantly greater percentage of all patients were treated in the combined program (47% vs. 20%, p = 0.008), and a significantly greater percentage of patients received systemic therapy (78% vs. 55%, p < 0.05). This juvenile localized scleroderma cohort is one of the largest reported from a single center and demonstrated an increase in the use of systemic therapy following the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012. Further studies on long-term treatment outcomes and therapeutic approaches utilized when first-line treatment failures occur are warranted.
- 6 June 2025
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 23 (1) , 1-7
Open AccessJuvenile localized scleroderma: a large retrospective cohort study from a tertiary care center
Juvenile localized scleroderma is a rare pediatric inflammatory disease that primarily affects the skin and subcutaneous tissue but also has the potential to impact deeper tissues and can be associated with extracutaneous manifestations, leading to substantial impairment and disability. Management approaches vary, but in recent years, expert groups have attempted to streamline the approach to care with consensus treatment plans. This retrospective cohort study included pediatric juvenile localized scleroderma patients with ≥ 3 years of follow-up identified within a 21-year period (1999–2020) at a single tertiary care pediatric hospital in the USA. Data on demographics, disease characteristics, and treatment trends were analyzed, with a focus on systemic versus topical therapy and treatment trends before and after the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012. A total of 101 juvenile localized scleroderma patients fulfilled our inclusion criteria. Sixty-three patients were treated with systemic therapy, and 38 were treated with topical therapy. Patients on systemic therapy were more commonly treated in a combined rheumatology-dermatology program (67%) or rheumatology clinic (30%), whereas those on topical therapy were primarily treated in a dermatology clinic (71%). Starting in 2013, a significantly greater percentage of all patients were treated in the combined program (47% vs. 20%, p = 0.008), and a significantly greater percentage of patients received systemic therapy (78% vs. 55%, p < 0.05). This juvenile localized scleroderma cohort is one of the largest reported from a single center and demonstrated an increase in the use of systemic therapy following the publication of the Childhood Arthritis and Rheumatology Research Alliance juvenile localized scleroderma consensus treatment plan in 2012. Further studies on long-term treatment outcomes and therapeutic approaches utilized when first-line treatment failures occur are warranted.
- 21 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (8) , 1092-1105
Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis
Objective: Disordered T peripheral helper (Tph)–B cell interactions have been implicated in several forms of inflammatory arthritis, including oligoarticular (oligo) juvenile idiopathic arthritis (JIA). We sought to evaluate the Tph–B cell axis in oligo JIA through an analysis of intra‐articular B cells.Methods: B cells from the blood and synovial fluid (SF) of 44 children with oligo JIA were compared to those from the blood and tonsils of controls. Flow cytometry, B cell receptor (BCR) repertoire analysis, and autoantibody profiling were used to characterize B cells.Results: Memory B (Bmem) cells and heterogeneous subsets of CD21lo B cells were enriched in oligo JIA‐SF versus blood of patients and controls. Compared to male patients, female patients with oligo JIA had greater proportions of intra‐articular Tph cells that expressed B cell help factors as well as Bmem cells, plasmablasts, and age‐/autoimmune‐associated B cells. The sex differences in B cells were observed only in the joints and were not found in the blood or tonsil, nor were they explained by other disease features such as age at onset, antinuclear antibody status, or severity. Bmem cells in SF from female patients displayed characteristics of autoreactivity, including longer complementarity determining region 3 lengths and increased usage of autoreactive BCR gene segments, which were not found in blood Bmem cells. A diverse array of autoantibodies accumulated in the SF of female patients with oligo JIA compared to the blood of patients with JIA and controls.Conclusion: These findings demonstrate prominent B cell dysregulation in oligo JIA and implicate sex as an important biologic factor in B cell responses in this disease.
- 21 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 77 (8) , 1092-1105
Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis
Objective: Disordered T peripheral helper (Tph)–B cell interactions have been implicated in several forms of inflammatory arthritis, including oligoarticular (oligo) juvenile idiopathic arthritis (JIA). We sought to evaluate the Tph–B cell axis in oligo JIA through an analysis of intra‐articular B cells.Methods: B cells from the blood and synovial fluid (SF) of 44 children with oligo JIA were compared to those from the blood and tonsils of controls. Flow cytometry, B cell receptor (BCR) repertoire analysis, and autoantibody profiling were used to characterize B cells.Results: Memory B (Bmem) cells and heterogeneous subsets of CD21lo B cells were enriched in oligo JIA‐SF versus blood of patients and controls. Compared to male patients, female patients with oligo JIA had greater proportions of intra‐articular Tph cells that expressed B cell help factors as well as Bmem cells, plasmablasts, and age‐/autoimmune‐associated B cells. The sex differences in B cells were observed only in the joints and were not found in the blood or tonsil, nor were they explained by other disease features such as age at onset, antinuclear antibody status, or severity. Bmem cells in SF from female patients displayed characteristics of autoreactivity, including longer complementarity determining region 3 lengths and increased usage of autoreactive BCR gene segments, which were not found in blood Bmem cells. A diverse array of autoantibodies accumulated in the SF of female patients with oligo JIA compared to the blood of patients with JIA and controls.Conclusion: These findings demonstrate prominent B cell dysregulation in oligo JIA and implicate sex as an important biologic factor in B cell responses in this disease.
- 8 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 537-547
EULAR /American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
Objective: To develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR). Methods: This international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients. Results: The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anemia, C‐reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort. Conclusion: These new classification criteria for pediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
- 8 May 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 537-547
EULAR /American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
Objective: To develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR). Methods: This international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients. Results: The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anemia, C‐reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort. Conclusion: These new classification criteria for pediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
- 27 February 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (6) , 1126-1128
Improvement in dermatomyositis-associated muscle disease with anifrolumab
We describe radiological and symptomatic improvement in two patients with dermatomyositis with recalcitrant muscle disease following off-label treatment with anifrolumab, a monoclonal antibody targeting type I interferon receptor recently approved by the FDA and EMA for the treatment of systemic lupus erythematosus.
- 27 February 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (6) , 1126-1128
Improvement in dermatomyositis-associated muscle disease with anifrolumab
We describe radiological and symptomatic improvement in two patients with dermatomyositis with recalcitrant muscle disease following off-label treatment with anifrolumab, a monoclonal antibody targeting type I interferon receptor recently approved by the FDA and EMA for the treatment of systemic lupus erythematosus.
- 1 June 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (8) , 811-817
Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease
Objective: To describe the clinical features of patients with congenital heart disease (CHD) who subsequently developed systemic juvenile idiopathic arthritis (sJIA).Methods: We conducted a retrospective review of patients diagnosed with CHD and sJIA at our institution. Detailed clinical, laboratory, and radiographic data were collected from the medical record and reviewed with each patient’s primary medical team.Results: Five patients with sJIA and CHD were identified. Each child had a unique cardiac anatomy, but all the patients required surgical repair during the first year of life. Four children had thymectomies at the time of cardiac surgery. Classic signs of sJIA such as fever (n = 5), rash (n = 5), and arthritis (n = 4) developed after surgical intervention in all the patients. The individuals in this cohort displayed risk factors associated with severe sJIA, including disease onset before 2 years of age (n = 5), elevated interleukin 18 levels (n = 5), baseline eosinophilia prior to initiation of biologic disease-modifying antirheumatic drugs (n = 4), and positivity for HLA-DRB1*15:01 alleles (n = 4). Macrophage activation syndrome (MAS) occurred in 3 patients and sJIA-associated lung disease (sJIA-LD) was identified in 4 patients. Two children died from complications of their cardiac and/or pulmonary disease.Conclusion: We identified an association between CHD and severe forms of sJIA. Although these findings will need to be confirmed in larger, multicenter cohorts, the results highlight the importance of considering a diagnosis of sJIA in children with CHD and remaining vigilant for complications such as MAS and sJIA-LD.
- 1 June 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (8) , 811-817
Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease
Objective: To describe the clinical features of patients with congenital heart disease (CHD) who subsequently developed systemic juvenile idiopathic arthritis (sJIA).Methods: We conducted a retrospective review of patients diagnosed with CHD and sJIA at our institution. Detailed clinical, laboratory, and radiographic data were collected from the medical record and reviewed with each patient’s primary medical team.Results: Five patients with sJIA and CHD were identified. Each child had a unique cardiac anatomy, but all the patients required surgical repair during the first year of life. Four children had thymectomies at the time of cardiac surgery. Classic signs of sJIA such as fever (n = 5), rash (n = 5), and arthritis (n = 4) developed after surgical intervention in all the patients. The individuals in this cohort displayed risk factors associated with severe sJIA, including disease onset before 2 years of age (n = 5), elevated interleukin 18 levels (n = 5), baseline eosinophilia prior to initiation of biologic disease-modifying antirheumatic drugs (n = 4), and positivity for HLA-DRB1*15:01 alleles (n = 4). Macrophage activation syndrome (MAS) occurred in 3 patients and sJIA-associated lung disease (sJIA-LD) was identified in 4 patients. Two children died from complications of their cardiac and/or pulmonary disease.Conclusion: We identified an association between CHD and severe forms of sJIA. Although these findings will need to be confirmed in larger, multicenter cohorts, the results highlight the importance of considering a diagnosis of sJIA in children with CHD and remaining vigilant for complications such as MAS and sJIA-LD.
- 15 February 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (5) , 616-626
Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale
Objective: Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcomes, including contractures, hemiatrophy, uveitis, and seizures. Despite improvements in treatment, >25% of patients with jLS have functional impairment. To improve patient evaluation, our workgroup developed the Localized scleroderma Total Severity Scale (LoTSS), an overall disease severity measure.Methods: LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multicriteria decision analysis. Feasibility was assessed in larger Childhood Arthritis and Rheumatology Research Alliance groups. Construct validity with physician assessment and inter‐rater reliability was assessed using case vignettes. Additional evaluation was performed in a prospective patient cohort initiating treatment.Results: LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by a strong positive correlation with the Physician Global Assessment (PGA) of severity and damage and weak positive correlation with PGA‐Activity, as expected. LoTSS was responsive, with a small effect size identified. Moderate‐to‐excellent inter‐rater reliability was demonstrated. LoTSS was able to discriminate between patient subsets, with higher scores identified in those with greater disease burden and functional limitation.Conclusion: We developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the major extracutaneous manifestations in LS. Our findings suggest LoTSS could aid assessment and management of patients and facilitate outcome evaluation in treatment studies. image
- 15 February 2024
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (5) , 616-626
Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale
Objective: Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcomes, including contractures, hemiatrophy, uveitis, and seizures. Despite improvements in treatment, >25% of patients with jLS have functional impairment. To improve patient evaluation, our workgroup developed the Localized scleroderma Total Severity Scale (LoTSS), an overall disease severity measure.Methods: LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multicriteria decision analysis. Feasibility was assessed in larger Childhood Arthritis and Rheumatology Research Alliance groups. Construct validity with physician assessment and inter‐rater reliability was assessed using case vignettes. Additional evaluation was performed in a prospective patient cohort initiating treatment.Results: LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by a strong positive correlation with the Physician Global Assessment (PGA) of severity and damage and weak positive correlation with PGA‐Activity, as expected. LoTSS was responsive, with a small effect size identified. Moderate‐to‐excellent inter‐rater reliability was demonstrated. LoTSS was able to discriminate between patient subsets, with higher scores identified in those with greater disease burden and functional limitation.Conclusion: We developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the major extracutaneous manifestations in LS. Our findings suggest LoTSS could aid assessment and management of patients and facilitate outcome evaluation in treatment studies. image